NEUPOGEN (FILGRASTIM)
- Chemotherapy-induced neutropenia
- Prevention of neutropenia from cancer chemotherapy
- Congenital neutropenia
- Cyclic neutropenia
- Hematopoietic syndrome of acute radiation syndrome
- Idiopathic neutropenia
- Neutropenia secondary to AML treatment
- Peripheral mobilization of hematopoietic stem cells
- Severe chronic neutropenia
300 mcg/0.5 mL injection syringe
- Inject 5 mcg/kg by subcutaneous route once daily
480 mcg/0.8 mL injection syringe
- Inject 5 mcg/kg by subcutaneous route once daily
300 mcg/mL injection solution
- Inject 5 mcg/kg by subcutaneous route once daily
480 mcg/1.6 mL injection solution
- Inject 5 mcg/kg by subcutaneous route once daily
AIDs-associated neutropenia
- Inject 5 mcg/kg by subcutaneous route once daily
- Inject 5 mcg/kg by subcutaneous route once daily for 2 weeks
- Inject 5 mcg/kg by subcutaneous route once daily for 4 weeks
- Inject 10 mcg/kg by subcutaneous route once daily for 2 weeks
- Inject 10 mcg/kg by subcutaneous route once daily for 4 weeks
- Inject 10 mcg/kg by subcutaneous route once daily
Congenital neutropenia
- Inject 6 mcg/kg by subcutaneous route 2 times per day
Cyclic neutropenia
- Inject 5 mcg/kg by subcutaneous route once daily
Drug-induced neutropenia
- Inject 5 mcg/kg by subcutaneous route once daily
- Inject 5 mcg/kg by subcutaneous route once daily for 14 days
- Infuse 5 mcg/kg over 15-30 minute(s) by intravenous route once daily
- Infuse 5 mcg/kg over 15-30 minute(s) by intravenous route once daily for 14 days
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily for 14 days
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily for 14 days
- Inject 1 milliliter (300 mcg) by subcutaneous route once daily
- Inject 0.5 milliliter (300 mcg) by subcutaneous route once daily
- Inject 1.6 milliliters (480 mcg) by subcutaneous route once daily
- Inject 0.8 milliliter (480 mcg) by subcutaneous route once daily
Hematopoietic syndrome of acute radiation syndrome
- Inject 10 mcg/kg by subcutaneous route once daily
Idiopathic neutropenia
- Inject 5 mcg/kg by subcutaneous route once daily
Myelodysplastic syndrome
- Inject 0.3 mcg/kg by subcutaneous route once daily
- Inject 10 mcg/kg by subcutaneous route once daily
- Infuse 50 mcg/m2 over 30 minute(s) by intravenous route once daily
- Infuse 400 mcg/m2 over 30 minute(s) by intravenous route once daily
Myeloid engraftment enhancement
- Inject 5 mcg/kg by subcutaneous route once daily
- Inject 10 mcg/kg by subcutaneous route once daily for 7 days
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily for 21 days
- Infuse 5 mcg/kg over 4 hour(s) by intravenous route once daily for 21Days
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily for 21 days
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily for21 days
- Infuse 10 mcg/kg over 4 hour(s) by intravenous route once daily
- Infuse 10 mcg/kg over 24 hour(s) by intravenous route once daily
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Infuse 5 mcg/kg over 4 hour(s) by intravenous route once daily
- Infuse 10 mcg/kg over 4 hour(s) by intravenous route once daily for 21 days
- Infuse 10 mcg/kg over 24 hour(s) by intravenous route once daily for 21 days
- Inject 10 mcg/kg over 4 hour(s) by subcutaneous route once daily
- Inject 10 mcg/kg over 4 hour(s) by subcutaneous route once daily for 21 days
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily
Neutropenia secondary to AML treatment
- Inject 5 mcg/kg by subcutaneous route once daily
- Inject 5 mcg/kg by subcutaneous route once daily for 14 days
- Infuse 5 mcg/kg over 15-30 minute(s) by intravenous route once daily
- Infuse 5 mcg/kg over 15-30 minute(s) by intravenous route once daily for 14 days
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily for 14 days
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily for 14 days
Peripheral mobilization of hematopoietic stem cells
- Inject 10 mcg/kg by subcutaneous route once daily
- Inject 10 mcg/kg by subcutaneous route once daily for 6 days
- Inject 10 mcg/kg by subcutaneous route once daily for 7 days
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily for6 days
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily for7 days
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily
Prevention of neutropenia from cancer chemotherapy
- Inject 5 mcg/kg by subcutaneous route once daily
- Infuse 10 mcg/kg over 4 hour(s) by intravenous route once daily
- Infuse 10 mcg/kg over 24 hour(s) by intravenous route once daily
- Inject 10 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Infuse 5 mcg/kg over 15-30 minute(s) by intravenous route once daily
- Inject 5 mcg/kg over 24 hour(s) by subcutaneous route once daily
- Infuse 5 mcg/kg over 24 hour(s) by intravenous route once daily
- None
Contraindicated
- None
Severe
Moderate
- Hycamtin
- topotecan
- Aortitis
Contraindicated
- Acute respiratory distress syndrome
- Alveolar hemorrhage
- Capillary leak syndrome
- Glomerulonephritis
- Leukocytosis
- Nontraumatic splenic rupture
- Sickle cell disease
Severe
Moderate
- Cutaneous vasculitis
NEUPOGEN (FILGRASTIM)
- Chemotherapy-induced neutropenia
- Prevention of neutropenia from cancer chemotherapy
- Congenital neutropenia
- Cyclic neutropenia
- Hematopoietic syndrome of acute radiation syndrome
- Idiopathic neutropenia
- Neutropenia secondary to AML treatment
- Peripheral mobilization of hematopoietic stem cells
- Severe chronic neutropenia
- None
- Arthralgias
- Bone pain
- Fever
- Headache disorder
- Hypesthesia
- Myalgias
- Nausea
- Pain
- Pruritus of skin
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Hypertension
- Injection site sequelae
- Leukocytosis
- Peritonitis
- Epistaxis
- Petechiae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Alveolar hemorrhage
- Anaphylaxis
- Aortitis
- Capillary leak syndrome
- Cutaneous vasculitis
- Glomerulonephritis
- Hemoptysis
- Hepatomegaly
- Nontraumatic splenic rupture
- Osteoporosis
- Pulmonary hemorrhage
- Splenomegaly
- Supraventricular arrhythmias
- Sweet's syndrome
- Thrombocytopenic disorder
Less Severe
- Alopecia
- Diarrhea
- Drug-exacerbated psoriasis
- Fatigue
- General weakness
- Hematuria
- Proteinuria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Filgrastim
Rare reports of development of MDS and AML with underlying congenital neutropenia and chronic use. Rare postmarketing reports of decreased bone density with extended use.
- 1 Day – 18 Years
- Rare reports of development of MDS and AML with underlying congenital neutropenia and chronic use. Rare postmarketing reports of decreased bone density with extended use.
Filgrastim
- Severity Level:
2
- Additional Notes: Insufficient human data; consider maternal treatment benefit
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Filgrastim
Poor oral bioavailability
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Poor oral bioavailability |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Chemotherapy-induced neutropenia | |
D70.1 | Agranulocytosis secondary to cancer chemotherapy |
Congenital neutropenia | |
D70.0 | Congenital agranulocytosis |
Cyclic neutropenia | |
D70.4 | Cyclic neutropenia |
Hematopoietic syndrome of acute radiation syndrome | |
T66.xxxA | Radiation sickness, unspecified, initial encounter |
T66.xxxD | Radiation sickness, unspecified, subsequent encounter |
Idiopathic neutropenia | |
D70 | Neutropenia |
D70.8 | Other neutropenia |
D70.9 | Neutropenia, unspecified |
Neutropenia secondary to AML treatment | |
D70.1 | Agranulocytosis secondary to cancer chemotherapy |
Peripheral mobilization of hematopoietic stem cells | |
Z52.011 | Autologous donor, stem cells |
Severe chronic neutropenia | |
D70.8 | Other neutropenia |
D70.9 | Neutropenia, unspecified |
0-9 | A-Z |
---|---|
D70 | Neutropenia |
D70.0 | Congenital agranulocytosis |
D70.1 | Agranulocytosis secondary to cancer chemotherapy |
D70.1 | Agranulocytosis secondary to cancer chemotherapy |
D70.4 | Cyclic neutropenia |
D70.8 | Other neutropenia |
D70.8 | Other neutropenia |
D70.9 | Neutropenia, unspecified |
D70.9 | Neutropenia, unspecified |
T66.xxxA | Radiation sickness, unspecified, initial encounter |
T66.xxxD | Radiation sickness, unspecified, subsequent encounter |
Z52.011 | Autologous donor, stem cells |